|
WO2005082887A1
|
|
Pyrimidine derivative
|
|
JP2005283380A
|
|
Method for measuring bioavailable steroid hormone
|
|
CA2518548A1
|
|
Peptide fragment of lyve-1 and antibody against the same
|
|
JP2005239578A
|
|
Medicine having both 5-ht1a-operating action and 5-ht3 antagonismic action
|
|
JP2005225844A
|
|
Agent for treatment of irritable bowel syndrome
|
|
JP2005225845A
|
|
Piperazinyl pyridine derivative
|
|
JP2004262799A
|
|
Three-dimensional structure of new antitumor agent soblidotin
|
|
JP2004257949A
|
|
Method of measuring trace in-vivo steroidal substance
|
|
EP1380840A1
|
|
Method of diagnosing breast cancer
|
|
JP2003238443A
|
|
Atrophying agent for prostatic capillary vessel
|
|
JP2003238411A
|
|
Agent for administration before prostatic operation
|
|
JP2003146972A
|
|
Carbostyril derivative
|
|
JP2005022972A
|
|
4-(4-pyridazinyl)pyrazole derivative
|
|
JP2002311010A
|
|
Method for determining dihydroavermectine
|
|
JP2002284679A
|
|
Stable solid preparation composition containing thyroid hormone
|
|
JP2002068965A
|
|
Single layer sugar-coated tablet and method for producing the same
|
|
JP2001151671A
|
|
Particle preparation having protrusion
|
|
JP2002030063A
|
|
Method for producing sulfamate compound
|
|
JP2002005931A
|
|
Screening method for carcinogenicity
|
|
CN1560051A
|
|
Substituted pyrazole compounds
|
